.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,014,846

« Back to Dashboard

Claims for Patent: 7,014,846

Title:Phosphate-binding polymers for oral administration
Abstract:Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
Inventor(s): Holmes-Farley; Stephen Randall (Arlington, MA), Manderville, III; W. Harry (Lynnfield, MA), Whitesides; George M. (Newton, MA)
Assignee: Genzyme Corporation (Cambridge, MA)
Application Number:10/766,638
Patent Claims: 1. A pharmaceutical composition comprising a carrier and a crosslinked, water insoluble polyallylamine homopolymer, wherein said polyallylamine homopolymer comprises repeat units represented by the structural formula: ##STR00028## wherein n is an integer, wherein said polyallylamine homopolymer is crosslinked with an epichlorohydrin crosslinking agent, and wherein the homopolymer is fully protonated, partially protonated or unprotonated.

2. The pharmaceutical composition of claim 1, wherein the amount of said crosslinking agent is about 2% to about 20% by weight of the polymer.

3. The pharmaceutical composition of claim 1, wherein said polyallylamine homopolymer is fully or partially protonated.

4. The pharmaceutical composition of claim 3, wherein said polyallylamine homopolymer is protonated with HCl.

5. The pharmaceutical composition of claim 4, wherein said polyallylamine homopolymer is partially protonated.

6. The pharmaceutical composition of claim 1, wherein said pharmaceutical composition consists essentially of one or more carriers and said polyallylamine homopolymer.

7. The pharmaceutical composition of claim 1, wherein said pharmaceutical composition consists of one or more carriers and said polyallylamine homopolymer.

8. The pharmaceutical composition at claim 1, wherein said pharmaceutical composition is in the form of a tablet or a capsule.

9. A method for removing phosphate from a patient, comprising orally administering to said patient a therapeutically effective amount of a composition comprising a crosslinked, water insoluble polyallylamine homopolymer, wherein said polyallylamine homopolymer comprises repeat units represented by the structural formula: ##STR00029## wherein n is an integer, and wherein the homopolymer is fully protonated, partially protonated or unprotonated.

10. The method of claim 9, wherein said polyallylamine homopolymer is crosslinked with an epichlorohydrin crosslinking agent.

11. The method of claim 10, wherein the amount of said crosslinking agent is about 2% to about 20% by weight of the polymer.

12. The method of claim 9, wherein said polyallylamine homopolymer is fully or partially protonated.

13. The method of claim 12, wherein said polyallylamine homopolymer is protonated with HCl.

14. The method of claim 13, wherein said polyallylamine homopolymer is partially protonated.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc